ArticleCureus2026
Delayed Corneal Endothelial Cell Loss Following CyPass Stent Insertion: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of delayed corneal endothelial cell loss (CECL) following CyPass® stenting in a 71-year-old female with normal-tension glaucoma. CECL is a known complication of the CyPass® stent, which resulted in its withdrawal from the market in 2018; however, the mechanism for CECL is often attributed to mechanical endothelial disruption from poorly positioned stents. In this case, our patient suffered around a 40% CECL, which first started five years following stent implantation and responded well to ripasudil therapy. This occurred despite it being optimally positioned, prompting an alternate explanation for the mechanism of CECL following CyPass® stent insertion. We propose three areas for future research, which may explain the CECL: mechanical stress, such as from device-cornea touching; inflammation, from a chronic foreign body reaction; and direct cytotoxicity from degradation of irradiated polyimide material. Further research is needed to establish the biocompatibility of irradiated polyimide in the eye, as well as the role of ripasudil in stabilizing minimally invasive glaucoma surgery-related CECL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.